PubMed · 9048537
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
J M Kelso. 1997. Study protocol on azelastine.. https://doi.org/10.1016/s1081-1206(10)63396-0
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Restenosis after percutaneous transluminal coronary angioplasty (PTCA) occurs due to vascular smooth muscle cell proliferation and migration. Recently, tranilast, an anti-allergic drug, has been used for the prevention of restenosis after PTCA. To determine the molecular mechanism involved, the effect of tranilast on the proliferation of human coronary smooth muscle cells (SMCs) was investigated. Tranilast arrested the proliferation of human coronary SMCs at the G0/G1 phase of the cell cycle. In association with this inhibitory effect, tranilast increased p21waf1 and p53 tumor suppressor factor, and decreased cyclin-dependent kinase 2 (CDK2) activity. These results suggest that tranilast inhibits the proliferation of human coronary SMCs during restenosis after PTCA via an induction of p21waf1 and p53. Tranilast may thus allow us to prevent restenosis after PTCA by interfering with this mechanism.
Explore the source record for details and available documents.
Resveratrol (1) and nine related hydroxystilbene compounds (2 approximately 9) isolated from plants were evaluated for the anti-allergic activities in vitro. Resveratrol (1) and rhapontigenin (5) demonstrated significant inhibitions upon the release of beta-hexosaminidase from the cultured RBL-2H3 cells in a dose-dependent manner and the IC50 values were calculated as 14 and 15 microM, respectively.